Clinuvel Pharmaceuticals completed ZEROKIN, a single-use device for subcutaneous delivery of controlled-release formulations, as the self-administered device market is projected to rise from US$27.1 billion in 2026 to US$40.5 billion by 2030. The device still requires Manufacturing and regulatory steps before human use.

Key Highlights

  • Clinuvel has submitted an intellectual-property application for ZEROKIN and plans to appoint a commercial manufacturer.
  • The device is intended to be registered as a Class II product through the FDA 510(k) pathway, alongside an EU CE-marking application.
  • ZEROKIN is designed for hospital administration or self-administration, depending on the medication.

The device is intended for formulations developed through the company’s research, development and innovation activities in Singapore.

ZEROKIN Moves Toward Manufacturing and Registration

Clinuvel (NASDAQ: CUVL) said the device will be used with novel controlled-release formulations, including approaches focused initially on melanocortins, the peptide family that includes afamelanotide. An intellectual-property application has been submitted, while a commercial manufacturer is to be appointed. Clinuvel also plans to submit a dossier for Class II registration through the U.S. Food and Drug Administration’s 510(k) pathway. The regulatory plan also includes an application for CE marking under European Union medical-device regulations. Clinuvel’s Chief Scientific Officer, Dr Dennis Wright, said the device followed clinical feedback on the use of SCENESSE and other peptides, and that the company would move toward finished manufacture and regulatory filing.

Market Growth Supports Self-Administration Focus

North America represented 42.4% of market Revenue in 2024, according to the company’s announcement. Demand has been linked in the release to chronic conditions and new therapeutic classes. Clinuvel’s initial formulation focus is melanocortins, including afamelanotide, while ZEROKIN is intended to accommodate controlled-release delivery.